title: The minimum important difference for the Pelvic Organ Prolapse-Urinary Incontinence Sexual Function Questionnaire.
abstract: OBJECTIVE
  Although the Pelvic Organ Prolapse-Urinary Incontinence Sexual Function Questionnaire (PISQ) is widely used to assess sexual function in women, the minimum important difference (MID) (defined as the smallest difference in scores of a patient-reported outcome measure that is perceived by patients as beneficial or harmful and which would lead the clinician to consider a change in treatment) is not known. The objective was to estimate the MID for the PISQ.
  
  
  METHODS
  Two study populations, one of women with overactive bladder (OAB) and urgency UI (UUI) treated with tolterodine in a placebo-controlled trial (cohort I), and one of women treated surgically for prolapse and/or UI (cohort II) were used. Cohort I anchors were the Overactive Bladder Questionnaire (OAB-q), the Patient Perception of Bladder Condition (PPBC), the Patient Perception of Treatment Benefit Questionnaire (PPTBQ), and the change in number of UUI episodes in bladder diaries. Distribution MIDs were also calculated.
  
  
  RESULTS
  In the anchor-based analysis, the MID values for changes in PISQ total scores at 3 months in cohort I were 5 points using the UUI anchor (diary-dry women), 5 points using the PPBC anchor, 5 points with the PPTBQ, and 9 points with the OAB-q. In cohort II, the MID at week 12 in PISQ total scores was 7 points in women with improved IIQ-7 scores. The distribution-based MID in PISQ total scores was 5.3 points in cohort I and 5.8 points in cohort II.
  
  
  CONCLUSIONS
  A reasonable estimate of MID for the PISQ total score is 6 points. Improvements that meet these thresholds may be considered clinically important.
authors.affiliation: Icahn School of Medicine at Mount Sinai, 1176 5th Avenue, Klingenstein Pavilion, 9th Floor, Box 1170, New York, NY, 10029, USA, mamta.mamik@gmail.com.
authors.forename: M M
authors.initials: MM
authors.lastname: Mamik
authors.forename: R G
authors.initials: RG
authors.lastname: Rogers
authors.forename: C R
authors.initials: CR
authors.lastname: Qualls
authors.forename: J D
authors.initials: JD
authors.lastname: Morrow
mesh_terms: D000328:Adult; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000627:therapeutic use; D017060:Patient Satisfaction; D056887:Pelvic Organ Prolapse / Q000150:complications / Q000523:psychology / Q000601:surgery*; D011788:Quality of Life; D012680:Sensitivity and Specificity; D012725:Sexual Behavior / Q000523:psychology*; D011795:Surveys and Questionnaires; D000068737:Tolterodine Tartrate / Q000627:therapeutic use; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000150:complications / Q000523:psychology / Q000628:therapy*; D053202:Urinary Incontinence, Urge / Q000150:complications / Q000523:psychology / Q000628:therapy*
chemical_list: D018727:Muscarinic Antagonists; D000068737:Tolterodine Tartrate